Most epilepsy relapses aren't about the drugs failing — they're about fixable problems. A new study found that nearly 70% of seizure relapses in newly diagnosed epilepsy patients were tied to modifiable factors like poor medication adherence and subtherapeutic dosing. Only 7% of patients actually met criteria for true drug-resistant epilepsy over five years.
When epilepsy patients have a breakthrough seizure, it's tempting to assume the medication isn't working — but a new study says clinicians should look closer before drawing that conclusion. A retrospective cohort study of 330 newly diagnosed epilepsy patients found that nearly 70% of seizure relapses over five years were linked to potentially modifiable factors, not drug resistance. The most common culprits? Poor medication adherence and inadequate dosing — not treatment failure.
The study, published in Epilepsia, tracked patients for five years after starting antiseizure medication (ASM). While treatment ineffectiveness grew as a cause of relapse over time (from 22% in year one to 41% by year five), poor adherence remained a persistent contributor throughout, accounting for 27%–38% of relapses annually. Subtherapeutic dosing was especially common in patients over 60, where lower doses were often prescribed out of caution.
Key Takeaways:
Why it matters: Misclassifying a patient as drug-resistant can lead to unnecessary treatment escalation. Identifying and addressing the real cause of a relapse — whether it's a missed dose or a dosing miscalculation — could meaningfully improve long-term outcomes for epilepsy patients.
